



**Press Release  
FY010 Results**

## **74% EBITDA improvement at Group level**

- **Yondelis sales increase by 70%.**
- **The Biopharmaceutical business reported 55% growth in sales with respect to 2009, accounting for 52% of the group total and exceeding the contribution from the Consumer Chemicals division.**
- **Group net sales rose by 24.4%.**
- **EBITDA improved 74% and net income attributable to the parent company rose 71.6% in 2010.**

**Madrid, 24 February 2011:** Zeltia Group's net revenues totalled 153.5 million euro in 2010, 24.4% more than in 2009 (123.4 million euro). This performance is primarily attributable to a 70% increase in Yondelis sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro in 2010 (51.1 million euro in 2009), of which 72.1 million correspond to Yondelis® (43.8 million euro in 2009).

The Biopharmaceutical segment accounted for 52% of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro in 2010, compared with 71.1 million euro in 2009).

EBITDA improved by 74% in 2010 to -3.9 million euro (-15.3 million euro in 2009).

Net income attributable to the parent company rose 71% with respect to 2009.

### **About Zeltia**

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

**For more information +34 91 444 4500**

This note is also available on the Zeltia web site: [www.zeltia.com](http://www.zeltia.com)